التفاصيل البيبلوغرافية
| العنوان: |
Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. |
| المؤلفون: |
Hasselt, J. G. Coen, Rizk, Matthew L., Lala, Mallika, Chavez‐Eng, Cynthia, Visser, Sandra A. G., Kerbusch, Thomas, Danhof, Meindert, Rao, Gauri, Graaf, Piet H. |
| المصدر: |
British Journal of Clinical Pharmacology; Jun2016, Vol. 81 Issue 6, p1113-1123, 11p |
| مصطلحات موضوعية: |
LUNG infections, IMIPENEM, PHARMACOKINETICS, LUNG diseases, KIDNEY diseases |
| مستخلص: |
Aims Several clinical trials have confirmed the therapeutic benefit of imipenem for treatment of lung infections. There is however no knowledge of the penetration of imipenem into the lung epithelial lining fluid (ELF), the site of action relevant for lung infections. Furthermore, although the plasma pharmacokinetics (PK) of imipenem has been widely studied, most studies have been based on selected patient groups. The aim of this analysis was to characterize imipenem plasma PK across populations and to quantify imipenem ELF penetration. Methods A population model for imipenem plasma PK was developed using data obtained from healthy volunteers, elderly subjects and subjects with renal impairment, in order to identify predictors for inter-individual variability (IIV) of imipenem PK. Subsequently, a clinical study which measured plasma and ELF concentrations of imipenem was included in order to quantify lung penetration. Results A two compartmental model best described the plasma PK of imipenem. Creatinine clearance and body weight were included as subject characteristics predictive for IIV on clearance. Typical estimates for clearance, central and peripheral volume, and inter-compartmental clearance were 11.5 l h-1, 9.37 l, 6.41 l, 13.7 l h-1, respectively (relative standard error (RSE) <8%). The distribution of imipenem into ELF was described using a time-independent penetration coefficient of 0.44 (RSE 14%). Conclusion The identified lung penetration coefficient confirms the clinical relevance of imipenem for treatment of lung infections, while the population PK model provided insights into predictors of IIV for imipenem PK and may be of relevance to support dose optimization in various subject groups. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Clinical Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder